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Genetically engineered mouse cancer models allow tumors to be imaged in vivo via co-expression of a
reporter gene with a tumor-initiating gene. However, differential transcriptional and translational
regulation between the tumor-initiating gene and the reporter gene can result in inconsistency between the
actual tumor size and the size indicated by the imaging assay. To overcome this limitation, we developed a
transgenic mouse in which two oncogenes, encoding P53R172H and KRASG12D, are expressed together with
two reporter genes, encoding enhanced green fluorescent protein (EGFP) and firefly luciferase, in a single
open reading frame following Cre-mediated DNA excision. Systemic administration of adenovirus
encoding Cre to these mice induced specific transgene expression in the liver. Repeated bioluminescence
imaging of the mice revealed a continuous increase in the bioluminescent signal over time. A strong
correlation was found between the bioluminescent signal and actual tumor size. Interestingly, all liver
tumors induced by P53R172H and KRASG12D in the model were hepatocellular adenomas. The mouse model
was also used to trace cell proliferation in the epidermis via live fluorescence imaging.We anticipate that the
transgenic mouse model will be useful for imaging tumor development in vivo and for investigating the
oncogenic collaboration between P53R172H and KRASG12D.
I
maging of tumors in vivo allows the tumor to be investigated directly in its natural environment, providing
invaluable information that could not be obtained otherwise. Although micro-computed tomography and
micro-positron emission tomography have been used for in vivo imaging of tumors in small animals, high cost
and technical difficulties have limited the adoption of these imaging techniques by researchers1. Optical imaging
techniques based on fluorescence and bioluminescence signals are cost-effective and easy to use, and are therefore
used widely in various fields of cancer research. For example, firefly luciferase has been applied to monitor
changes in tumor sizes in vivo following transplantation of luciferase-expressing tumor cells into immune-
deficient mice2. Green fluorescent protein (GFP) has also been used successfully to monitor tumor growth and
metastasis in vivo following transplantation of GFP-expressing cancer cells3,4.
Because of the utility of reporter transgenes in imaging studies, transgenic mouse models have been developed
in which a gene encoding luciferase or GFP is co-expressed with a tumor-initiating oncogene, thus allowing
tumor developments to be monitored via bioluminescence or fluorescence5–9. An oncogene and a reporter gene
can be co-expressed from separate promoters5,7,8, or a single promoter via internal ribosome entry site (IRES)-
mediated expression6,9. One limitation of both approaches is that expression of an oncogene does not always
accompany expression of a reporter gene, owing to, for example, differential transcriptional regulation between
the separate promoters, or variation in IRES-mediated expression10,11. Thus, the reliability of the reporter in the
transgenic mouse models is sometimes called into question.
Recently, the 2A sequence was used successfully to express multiple transgenes in a single open reading frame
by placing it between transgenes12–14. The 2A sequence encodes a short peptide (2A peptide) of,20 amino acids
and was originally found in picornaviruses, in which multiple proteins are derived from a large polyprotein.
Formation of a peptide bond at a specific site within the 2A peptide is inhibited during the translational process,
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resulting in the release of the preceding protein, while ribosomes
continue the translation for synthesis of the next protein. Notably,
stoichiometric production has been verified among proteins co-
expressed from a 2A sequence-containing multi-cistronic vector,
suggesting that the expression levels of a reporter gene co-expressed
with a gene of interest via 2A-mediated ribosome skipping may
faithfully represent the expression levels of the gene of interest12.
Here, we report a transgenicmousemodel for cancer, inwhich 2A-
mediated co-expression is used to express two oncogenes together
with two reporter genes encoding enhanced GFP (EGFP) and firefly
luciferase. Upon DNA excision by Cre, all four transgenes are
expressed. We selected oncogenes encoding a constitutively active
form of KRAS (KRASG12D) and a gain of function mutant of P53
(P53R172H), to efficiently induce tumors. KRASG12D leads to constitu-
tive activation of the Ras signaling pathway, and is associated with
various types of human cancer15. P53R172H (the murine equivalent of
human P53R175H) is known to display novel oncogenic properties
during cancer progression and promotion16–19. In this study, we also
investigated the oncogenic collaboration between P53R172H and
KRASG12D in the liver.
Results
Generation of the 2PLEASE mouse (2A-connected P53R172H, Luci-
ferase, EGFP, and KRASG12D expression induced by CRE). With
the goal of performing live imaging of tumor growth both micro-
scopically and macroscopically, we employed EGFP together with
firefly luciferase (hereafter termed ‘‘luciferase’’) as reporters. A
constitutively activated form of RAS, KRASG12D was selected as the
tumor-initiating oncogene. Owing to the inefficiency of tumor
induction by activated RAS alone, a gain-of-function mutant
P53R172H was selected as a collaborating partner for KRASG12D,
because of its various anticipated roles in tumor development20,21.
To validate the increased tumorigenic potential of co-expressed
P53R172H and KRASG12D, we performed a soft agar assay for
anchorage-independent cell growth and a proliferation assay under
low serum conditions using cell lines stably expressing both
oncogenes. Co-expression of P53R172H and KRASG12D rendered cells
proliferative under both assay conditions (see Supplementary Fig. S1
online), suggesting that they acquired the characteristics of tumor
cells. Expression of P53R172H or KRASG12D alone failed to induce
significant cell proliferation in either assay, justifying the use of
both oncogenes to efficiently induce tumors in transgenic animals.
To express the two oncogenes and the two reporter genes (four
transgenes in total) simultaneously in a single open reading frame,
the DNA sequence encoding the Thosea asigna virus (TaV) 2A pep-
tide was inserted between the transgenes, in-frame (Fig. 1A). Because
expression of these oncogenes from conception would likely have a
detrimental effect on animal development, we chose to control
expression of the transgenes using the Cre-mediated recombination
strategy. Insertion of the lacZ-neomycin fusion gene (b-geo), flanked
by loxP sites, immediately prior to the four transgenes would allow b-
geo to be expressed until Cre induces DNA recombination between
the loxP sites (Fig. 1A). One concern with this Cre-mediated trans-
gene expression strategy was that abrupt expression of the reporters
EGFP and luciferase in an adult tissue following Cre-mediated DNA
excisionmight induce an immune response, leading to a cytotoxic T-
lymphocyte (CTL) response directed at cells expressing the pro-
teins22,23. To minimize the CTL response, a DNA sequence encoding
the predicted immunodominant epitope regions of EGFP and luci-
ferase in C57BL/6 mice24,25 was inserted in-frame within the b-geo
gene segment, generating the ‘‘b-geo-epi’’ gene, which was placed
immediately prior to the four transgenes (Fig. 1A). The resulting
plasmid is referred to as the ‘‘2PLEASE’’ plasmid.
To assess whether Cre tightly regulates the switch of gene express-
ion in this construct, cells were transfected with the 2PLEASE plas-
mids in the presence or absence of Cre. As shown in Fig. 1B–1D, all
transgenes (i.e., genes encoding P53R172H, luciferase, EGFP, and
KRASG12D) were expressed only in the presence of Cre. This confirms
that expression of the four transgenes is tightly regulated by the Cre-
loxP system.
b-geo protein was detected successfully in the original construct by
Western blotting; however, the replacement of b-geo with b-geo-epi
resulted in no detectable signals of the correct size (see Supple-
mentary Fig. S2 online). When b-geo-epi was replaced by b-geo in
the same vector, the protein was detected again (Supplementary Fig.
S2 online). This suggests that the insertion of the epitope in the
middle of the b-geo protein likely led to mis-folding and subsequent
degradation of the chimeric protein26,27. Fusion of the epitope to the
N- or C-terminal of the b-geo protein would likelyminimize themis-
folding. However, we chose the degradation-prone b-geo-epi con-
struct for the microinjection experiment because we think that
degradation of the b-geo protein could reduce the possible toxicity
caused by ubiquitous protein expression. Microinjection of the
2PLEASE plasmids into pronuclei of the C57BL/6 genetic back-
ground resulted in three transgenic founders. The transgenic foun-
ders were bred with R26-Cre-ERT2 mice28 in which Cre can be
ubiquitously activated by treatment with tamoxifen. At 15 days
post-tamoxifen administration, double-transgenic offspring of each
line were assayed for bioluminescence (see Supplementary Fig. S3
online). In line 20, strong bioluminescence signals were detected
from the whole body, whereas signals were not detected in mice of
all other lines. Thus, mice from line 20 were used for subsequent
studies and are hereafter referred to as the ‘‘2PLEASE mice’’.
Quantitative PCR showed that the 2PLEASE mice carry five copies
of the transgene (Supplementary Fig. S3 online). The transgene was
stably transmitted to the next generation (up to the sixth generation,
to date).
Induction and bioluminescence imaging of liver tumors in the
2PLEASE mice. As described above, the 2PLEASE mice were
designed to express two oncogenes along with reporter genes
encoding EGFP and luciferase, upon Cre-mediated DNA excision.
Oncogene-induced cell proliferation is expected to generate foci
within tissues where fluorescent and bioluminescent signals accu-
mulate as a result of the expression of EGFP and luciferase. Thus, a
time-dependent increase in bioluminescent signals emanating from
a particular location within organ can, therefore, be an indicator of a
tumor growth in this model.
We chose the liver as the organ in which to test whether tumors
can be induced by co-expression of P53R172H and KRASG12D, and
whether repeated bioluminescence imaging of mice could trace the
growth of these tumors. To induce expression of the four transgenes
specifically in the liver, the 2PLEASE mice were intravenously admi-
nistered a Cre-expressing adenovirus with a high tropism for hepa-
tocytes29. Bioluminescence imaging, performed at 2, 4, and 6months
post-adenovirus administration, revealed increases in biolumin-
escent signals in the depilated abdominal areas of 12 of 23 mice
(Fig. 2A,B). Notably, mice exhibiting strong bioluminescent signals
showed larger tumors in the liver, compared to those with weak or
moderate bioluminescent signals (see Fig. 2A and Supplementary
Fig. S4 online). To test the reliability of bioluminescent signals for
monitoring tumor growth further, a liver cancer model was
developed via the hydrodynamic transfection method30. Hepatic
delivery of a mixture of transposons expressing KRASG12D, short
hairpin RNA down-regulating p53 (shp53) and luciferase rapidly
induced tumors in the liver (see Supplementary Figs. S5 and S6
online). Increases in bioluminescent signals were well correlated with
actual tumor growth, further supporting the reliability of biolumin-
escence imaging in monitoring tumor growth (Supplementary Fig.
S6 online).
The 11 mice that did not show an increase in bioluminescent
signals following adenovirus administration possessed livers free
www.nature.com/scientificreports
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from hyperplastic nodules (data not shown). No increases in bio-
luminescent signals or hepatic tumors were detected in mice treated
with adenovirus encoding EGFP (Fig. 2C). These data indicate that
transgene expression can be temporally and spatially regulated, that
hepatic tumors can be induced via expression of P53R172H and
KRASG12D, and, finally, that bioluminescence imaging can be effi-
ciently applied to monitor tumor growth in the 2PLEASE mouse
model.
The characteristics of liver tumors induced by P53R172H and
KRASG12D. Histological examination of liver tumors harvested
from the 2PLEASE mice revealed mass-forming foci of altered hepa-
tocytes. The lesions showed the typical morphology of glycogen-
storing foci. Hepatocytes in the foci were enlarged, owing to
massive glycogen storage (as indicated by a positive periodic acid-
Schiff (PAS) reaction) and the presence of fat vacuoles (Fig. 3A). All
tumor lesions examined were diagnosed as hepatocellular adenomas,
based on published criteria31. Progression to carcinoma was not
observed, even in tumors of ,1 cm in diameter that were
harvested at 8 months post-adenovirus administration.
To investigate the molecular characteristics of the tumors, the
expression levels of selected genes were analyzed by quantitative
RT-PCR (qRT-PCR) (Fig. 3B). Overexpression of P53 and KRAS
was confirmed in tumors from 2PLEASE mice, compared to normal
livers, presumably owing to the transgenic expression of P53R172H and
KRASG12D. The tumors also overexpressed cell cycle-related genes,
such as CyclinE1, CCNB2 and CDK1, indicative of elevated cellular
proliferation. Consistent with the increase in fat vacuoles in the
tumors, up-regulation of genes related to lipogenesis (SCD1,
FASN, and ACLY) was detected. Down-regulation of Acox1, a gene
involved in lipid catabolism, was observed in the tumors. No signifi-
cant differences were found between tumors and normal tissues in
the mRNA levels of genes related to the epithelial-mesenchymal
transition (Twsit1 and Zeb1). Interestingly, the expression level of
a-fetoprotein (AFP), a putative hepatocellular carcinoma (HCC)
marker, was significantly higher in tumors compared to normal liver
Figure 1 | Transgene expression from the 2PLEASE plasmid upon Cre-mediated DNA excision. (A) Schematic illustration of transgene expression
following Cre-mediated DNA excision. The epitope-containing b-geo (b-geo-epi) is expressed from the 2PLEASE plasmid in the absence of Cre.
Following Cre-mediated DNA recombination between the two loxP sites, P53R172H, luciferase, EGFP, and KRASG12D are expressed. (B) Fluorescence
imaging of cells transfected with the 2PLEASE plasmid in the absence (left) and presence (right) of Cre. (C) Western blotting shows tight regulation of
transgene expression of EGFP, P53 and Ras from the 2PLEASE plasmid. The blots were performed under the same experimental condition except for
blotting with different primary antibodies. These blots were shown as cropped images (D) Luminescent signals from cells transfected with the 2PLEASE
plasmid increased by,1000-foldwhenCre was co-expressed, compared to cells in whichCre was not co-expressed, which displayed a background level of
luminescence.
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tissue (p , 0.05). This is not consistent with the histopathological
results, which found no signs of HCC in all lesions investigated.
Because AFP can be up-regulated by various pathological condi-
tions32,33, its reliability as a HCCmarker should be carefully considered.
An alternative tumor model expressing P53R172H and KRASG12D
shows liver tumor incidences and histological features similar to
those of the 2PLEASE model. Expression of P53R172H and KRASG12D
in the livers of the 2PLEASE mice did not efficiently induce tumors;
an incidence of ,50% was observed by 6 months post-adenovirus
administration. Furthermore, the tumors that did arise failed to
progress to carcinoma. The adenoviral vector used for Cre
expression may have induced an immune response to cells infected
with the virus. In addition, although they are fewer than 20 amino
Figure 2 | Repeated bioluminescence imaging of the 2PLEASE mice. (A) Pseudocolor images of tumor growth in the liver of 2PLEASE mice.
Bioluminescence imaging was performed at 2, 4, and 6 months post-administration of adenovirus encoding Cre. Images of two representative mice are
presented. Note the continuous increase in the signals from the abdominal regions of the same mice. Gross morphology of the livers harvested from the
same mice (bottom right panels) confirms the correlation between the bioluminescent signals and the actual tumor sizes. (B) Average bioluminescence
signals from the abdominal regions of the 2PLEASEmice (n 5 23) at the indicated time-points after adenovirus injection. (C) Pseudocolor images of the
abdominal regions of the 2PLEASEmice at 8 months post-treatment with control adenovirus (Ad-EGFP) and adenovirus encoding Cre (Ad-Cre). Livers
harvested from the mice are presented below.
www.nature.com/scientificreports
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Figure 3 | Characteristics of liver tumors harvested from 2PLEASE mice. (A) A typical focus of altered hepatocytes detected in the liver of a 2PLEASE
mouse (H&E staining, upper left panel) already presenting as amass forming hepatocellular adenoma.Highermagnification (uppermiddle panel) reveals
enlarged hepatocytes with small lipid vacuoles. Massive glycogen storage is evident in the PAS staining (upper right panel). Another example of a
glycogen-storing focus in the liver (PAS staining, lower left panel). Fluorescence imaging shows GFP expression in cells in the nodule (lower middle
panel), confirming transgene expression following Cre-mediated DNA excision. Beneath the region containing green fluorescent cells are normal
hepatocytes that are GFP negative. Hepatocytes in this focus are also PAS-reactive (lower right panel). Scale bars, 250 mm for left panels and 50 mm for
middle and right panels. (B) Comparison of mRNA levels of selected genes. Quantitative RT-PCR was performed to compare the expression levels of the
indicated genes between normal liver tissue (white bar) and liver tumors (black bar). Relative expression levels are shown. Single asterisks indicate
p , 0.05 and double asterisks indicate p , 0.01.
www.nature.com/scientificreports
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acids long, truncated 2A peptides attached to P53R172H and KRASG12D
may have modified the function of the onco-proteins. To rule out the
possibility that the adenovirus or 2A peptides influenced tumor
development, we utilized an alternative transgenic mouse model
simultaneously expressing P53R172H and KRASG12D. The alternative
model was developed via a hydrodynamics-based transfection
method, coupled with the Sleeping Beauty transposon system,
which we have successfully used previously to generate various
transgenic models for liver cancer30,34. Transposons encoding
P53R172H and KRASG12D were mixed with plasmids expressing the
Sleeping Beauty transposase and then hydrodynamically delivered
to the liver (Fig. 4A). Livers harvested at 3 months post-
hydrodynamic injection (PHI) contained hyperplastic nodules in
50% of mice (Table 1). Tumors induced by P53R172H and KRASG12D
in this model showed few signs of malignancy; similar to tumors
found in the 2PLEASE model (Fig. 4B middle panels). Thus, it is
not likely that the adenovirus and the 2A peptide used in the
2PLEASE mouse affected tumor development in the liver.
In contrast, highly malignant liver tumors developed in mice
expressing KRASG12D and short hairpin RNA down-regulating p53
(shp53) by 1 month PHI (Fig. 4B right panels). These tumors were
solid and diagnosed as malignant hepatocellular carcinomas. Tumor
cells were extremely pleomorphic with highly atypical nuclei. The
tumors contained cells of highly undifferentiated morphology and
many giant tumor cells. Kaplan–Meier survival analysis also revealed
the existence of a highly significant difference in survival between
mice expressing KRASG12D plus shp53 and those expressing
KRASG12D plus P53R172H (Fig. 4C, p, 0.0001). No tumors were found
in livers expressing KRASG12D and EGFP (Fig. 4B left panels), imply-
ing that KRASG12D alone cannot induce liver tumors. Furthermore,
no pre-neoplastic or neoplastic lesions were found in livers expres-
sing P53R172H or shp53 alone (data not shown).
To enhance liver tumor development in the 2PLEASE model,
suppression of wild-type p53was attempted via hydrodynamic deliv-
ery of transposons expressing shp53. To express P53R172H and
KRASG12D (via Cre-mediated transgenic switching) together with
shp53 in the same cells, a chimeric transposon vector was employed
that expresses both shp53 and Cre (see Supplementary Fig. S5
online). Tumor development was increased dramatically in the liver
as multiple large tumor nodules were observed at 7 weeks post-
hydrodynamic transfection (Fig. 5A). Bioluminescence imaging
revealed increases in signal intensity from the abdominal area over
the 7-week period and corresponded well to tumor development
(Fig. 5A). Strong green fluorescence was observed from tumors
ex vivo, confirming transgenic expression in the 2PLEASE mice
following Cre-mediated DNA excisions (Fig. 5B left panel). His-
topathologic examination revealed that all tumors consisted of
hepatocellular carcinomas and the tumor cells were highly undiffer-
entiated with atypical nuclei (Fig. 5B right panel). Thus, the down-
regulation of wild-type p53 together with the expression of P53R172H
and KRASG12D dramatically accelerated tumor growth and promoted
hepatocellular carcinomas.
Induction of transgene expression in skin cells of 2PLEASE mice.
To investigate whether expression of P53R172H and KRASG12D is
capable of inducing skin cancer and whether tumor growth in skin
can be monitored via in vivo imaging of the co-expressed reporters,
2PLEASEmice were crossed with R26-Cre-ERT2mice and the double
transgenic offspring (2PLEASE; R26-Cre-ERT2) were treated
topically with tamoxifen on the dorsal skin following depilation.
Bioluminescence imaging performed at one week post-treatment
revealed strong signals on the depilated skin of the tamoxifen-
treated mice, while background signals were detected from vehicle-
treated mice (Fig. 6A). Furthermore, in vivo fluorescence imaging
showed that epidermal cells on the basal layer of tamoxifen-treated
mice exhibited green fluorescence (Fig. 6B). Thus, bioluminescence
and in vivo fluorescence imaging confirmed robust expression of the
transgenes in the skin following treatment with tamoxifen. However,
no increases in bioluminescent signals were observed over several
months in the tamoxifen-treated skin, strongly suggesting that the
tumor did not develop in the skin (Fig. 6C). Consistent with the
bioluminescence imaging data, no tumors were detected on the
skin of 11 double-transgenic mice until 8 months post-tamoxifen
treatment (data not shown). Interestingly, one mouse, excluded
from the in vivo imaging experiment due to a severe injury to the
depilated skin, developed skin tumors at about 2 months post-
tamoxifen treatment (see Supplementary Fig. S7 online). Live
imaging showed strong bioluminescence and green fluorescence
signals from the tumor (Supplementary Fig. S7 online). Histo-
pathologic examination revealed that the tumor was a well-
differentiated squamous cell carcinoma of the skin. These data
suggest that co-expression of KRASG12D and P53R172H is not
sufficient to induce skin tumors, which might require an additional
tumor-promoting condition, such as inflammation, for efficient
development of skin cancer35,36.
Imaging of clonal development of epidermal cells following
transgene expression. Previously, we developed the Stop-EGFP
mouse, in which EGFP is randomly expressed in skin cells, and
successfully used the mouse to trace clonal growth of epidermal
stem cells via in vivo fluorescence imaging37,38. We therefore
attempted to trace a clonal lineage of skin cells expressing P53R172H
and KRASG12D by means of fluorescence imaging of co-expressed
EGFP. For this purpose, a low dose of tamoxifen was applied
topically to depilated skin of double-transgenic (2PLEASE; R26-
Cre-ERT2) mice to reduce the frequency by which Cre induced
DNA recombination (i.e., transgenic switching), thus guaranteeing
the clonality of observed cell lineages.
Onemonth after the low-dose tamoxifen application, in vivo fluor-
escence imaging revealed several green fluorescent patches, each
containing between one and four adjacent corneocytes, within a skin
area of 1 3 1 cm (Fig. 7A). No green fluorescent cells were observed
in the skin of vehicle-treated double transgenic offspring, or
2PLEASE mice treated with tamoxifen (data not shown).
At 4 months post-tamoxifen administration, repeated imaging of
the same skin area revealed green fluorescent patches that were gen-
erally similar in size to those seen at the earlier time-point (i.e.,
between one and four adjacent corneocytes on the skin surface).
However, larger patches containing as many as 20 corneocytes
(Fig. 7B) were occasionally observed, indicative of proliferation
and clonal expansion of epidermal cells expressing KRASG12D and
P53R172H since the initial imaging phase. The data suggest that
P53R172H and KRASG12D can promote cellular proliferation in the skin
although the oncogenes are not strong enough to induce skin tumors.
Discussion
In this study, we developed a transgenic tumor model in which two
onco-proteins (P53R172H and KRASG12D) and two reporters (firefly
luciferase and EGFP) are expressed from a single open reading frame
uponCre-mediated DNA excision. Liver tumors were induced by the
expression of P53R172H and KRASG12D in 2PLEASE mice following
Cre-mediated DNA excision and subsequently imaged in vivo via
the co-expressed reporters. The bioluminescent signals were well
correlated with actual tumor sizes, demonstrating the utility of this
novel mouse model for live imaging of tumors.
Tumors in the liver expressing P53R172H and KRASG12D failed to
progress to carcinoma, whereas P53 inactivation (via short hairpin
RNA) in combination with KRASG12D expression induced highly
malignant carcinoma. The reason for the apparent inefficiency of
P53R172H to cooperate with KrasG12D to induce hepatic carcinoma is
unknown from our study. P53R172H is known to function as a gain-of-
function mutant, rather than simply inactivating wild-type P53 as a
www.nature.com/scientificreports
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dominant negativemutant18,19. Lines of evidence have shown that the
spectra and characteristics of tumors induced by P53R172H are quite
different from those of tumors induced by inactivation of wild-type
p5316,17. Of note, the tumorigenic function of P53R172H seems highly
dependent on the presence of wild-type P53. P53R172H knock-inmod-
els feature inefficient tumor induction in mice heterozygous for
P53R172H (P53R172H/1, thus maintaining one allele of the wild-type
p53), compared to homozygous mice (P53R172H/R172H, thus containing
no wild-type p53 alleles)16,17. Using a knock-in mouse model hetero-
zygous for P53R172H (P53R172H/1) Tuveson et al. showed that all of the
Figure 4 | Generation of liver-specific transgenic models via the hydrodynamic transfection method. (A) Schematic illustration of the experimental
procedure to generate transgenic livers expressing KRASG12D plus EGFP (control), KRASG12D plus P53R172H, and KRASG12D plus shp53. The indicated
plasmids were mixed and hydrodynamically delivered to the liver. (B) Gross morphology and H&E staining of a representative liver from each group.
While the control group shows no altered hepatocytic foci (upper left panel), single, small nodules were found in the livers of 50% of the KRASG12D plus
P53R172H mice at 3 months post-hydrodynamic injection (upper middle panel). KRASG12D plus shp53 mice at 1 month post hydrodynamic injection had
numerous hepatocellular tumors (upper right panel) characterized by high pleomorphism and dedifferentiation of malignant hepatocytes (lower right
panel). Scale bars, 100 mm. (C) Kaplan–Meier survival curves of mice expressing shp53, P53R172H and EGFP in addition to KRASG12D. Differences in
survival were highly significant between the KRASG12D plus shp53 and KRASG12D plus P53R172H groups (p , 0.0001).
www.nature.com/scientificreports
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pancreatic tumors that developed in the mice displayed p53 loss of
heterozygosity (LOH)20, resulting in the deletion of the wild-type
allele of p53. Thus, the presence of the wild-type allele of p53 would
likely inhibit the oncogenic properties of P53R172H.
To suppress wild-type p53 with the transgene expression simulta-
neously, 2PLEASE mice were hydrodynamically injected with trans-
poson vectors co-expressing shp53 and Cre. Of note, liver tumors
developed rapidly within 2 months with concomitant increases in
bioluminescent signals and all progressed to malignant hepatocellu-
lar carcinomas. To study the molecular pathways promoting the
development of hepatocellular carcinoma and/or accelerate tumor
formation, similar composite transposon vectors can be developed
that co-express another oncogene (such as cMyc or an activated b-
catenin) together with Cre39,40. Hydrodynamic delivery of such trans-
posons would enhance tumor growth in the liver of 2PLEASE mice,
and can bemonitored via bioluminescence imaging. Further, it could
be investigated whether additional oncogenes can promote the trans-
ition from hepatocellular adenoma (induced by P53R172H plus
KRASG12D) to carcinoma.
Although robust expression of transgenes was confirmed via in
vivo fluorescence imaging and bioluminescence imaging in the skin
(Figure 6 A, B), skin tumors did not develop in double-transgenic
(2PLEASE; R26-Cre-ERT2) mice following topical application of
tamoxifen. Interestingly, squamous cell carcinoma of the skin was
found in one mouse that had a severe wound on tamoxifen-treated
skin, which was accidentally caused by another male housed in the
same cage. Our highly speculative idea is that injury-mediated
inflammation may have promoted skin cancer in this mouse35,36. It
would be interesting to see how treatment with an agent inducing
skin inflammation, such as 12-O-tetradecanoylphorbol-13-acetate
(TPA), affects the development of skin cancer in the 2PLEASE
model. Using a low-dose scheme of tamoxifen treatment, we induced
transgene switching in skin cells at a low frequency in 2PLEASE;
R26-Cre-ERT2 mice. Clonal development of skin cells due to
increased cellular proliferation induced by P53R172H plus KRASG12D
was observed via in vivo fluorescence imaging. It would also be
interesting to investigate how these cells behave following treatment
with TPA via repeated in vivo fluorescence imaging over time.
One potential problem with 2PLEASE mice is that they carry
multiple copies of the transgenes. Because of the presence of multiple
loxP sites, DNA recombination by Cre might result in unexpected
breakdown of the transgene copies in the genome of 2PLEASE mice.
The knock-in strategy will resolve this issue and is expected to refine
the current 2PLEASE model41,42.
Methods
Plasmids. Plasmids harboring cDNA encoding firefly luciferase and EGFP were kind
gifts from Dr. Rabinovich43 and Dr. Okabe44, respectively. The plasmid Z/EG, a
generous gift from Dr. Lobe45, was modified to construct the plasmid, 2PLEASE.
Construction of 2PLEASE was performed in two steps. First, to minimize the
cytotoxic T-lymphocyte (CTL) response to the reporter proteins, DNA sequences
encoding predicted immunodominant CTL epitopes of EGFP and firefly luciferase in
C57BL/6 mice (DTLVNRIEL and LMYRFEEEL, respectively) were inserted, in-
frame, into the b-geo cDNA, after digesting Z/EG with the MscI restriction
enzyme22,23. The resulting plasmid is referred to as Zepi/EG. Next, the cDNAs
encoding the four transgenes were substituted for EGFP cDNA in the Zepi/EG. Prior
to the substitution, to express the four transgenes in a single open reading frame, the
termination codons located in the cDNAs encoding P53R172H, luciferase, and EGFP
were removed, and then the DNA sequence encoding the Thosea asigna virus (TaV)
2A peptide with a GSG linker at the N-terminus (i.e.,
GSGEGRGSLLTCGDVEENPGP) was inserted, in-frame, between the cDNAs13.
Transfection, Western blotting, and in vitro reporter assays. NIH3T3 cells (CRL-
1658; ATCC, Manassas, USA) were transiently transfected with 1 mg of 2PLEASE
plasmid and 1 mg of either pBS185CMV-Cre (ADDGENE #11916) or an empty
vector (a negative control), using FuGENE HD Transfection Reagent (Promega,
Madison, USA), according to themanufacturer’s instructions. Cells were harvested at
2 days post-transfection and lysed in 1 3 RIPA buffer (#9806; Cell Signaling).
Western blotting experiments were performed using standard methods. Anti-p53
(#2524), anti-GFP (#2555) and anti-LacZ (#2372) primary antibodies were purchased
from Cell Signaling Technology, and anti-Kras (sc-30) and anti-b-actin (sc-47778)
were purchased from Santa Cruz Biotechnology. Horseradish peroxidase (HRP)-
conjugated anti-mouse IgG (sc-2005, SantaCruz) and anti-rabbit IgG (A0545, Sigma)
were used as secondary antibodies. Fluorescence imaging of transfected cells was
performed at 2 days post-transfection, using an invertedmicroscope (IX71, Olympus,
Japan). Luciferase activity was measured using the Dual-Luciferase Reporter Assay
System (Promega), according to the manufacturer’s instructions.
Generation of stable cell lines and cell growth assays. Stable cell lines were generated
by transfection of NIH3T3 cells with plasmids encoding the respective oncogenes,
and subsequent selection of transfected cells using a G418-containingmedium. A soft
agar assay for anchorage-independent cell growth and a proliferation assay under a
low serum condition were performed following standard protocols46. For the low
Table 1 | Tumor incidence in the liver
Genes KRASG12D 1 EGFP KRASG12D 1 P53R172H KRASG12D 1 shp53
Tumor incidence*(%) 0/10 (0%) 10/20 (50%) 10/10 (100%)
*Livers were harvested at 3 months PHI for the KRASG12D 1 EGFP and KrasG12D 1 P53R172H groups. For the KRASG12D 1 shp53 group, livers were harvested at 1 month PHI because signs of illness were
present.
Figure 5 | Liver tumor development was enhanced in the 2PLEASE
model by the suppression of wild-type p53. (A) Bioluminescence imaging
of 2PLEASE mice was performed at 1 and 7 weeks post-hydrodynamic
delivery of transposons co-expressing shp53 and Cre. Gross morphologies
of livers harvested at the time points are shown below. (B) Green
fluorescence imaging of a representative tumor harvested at 7 weeks post-
hydrodynamic injection (left panel) and H&E staining of the tumor (right
panel). Scale bars, 200 mm.
www.nature.com/scientificreports
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serum condition, Dulbecco’s modified Eagle’s medium (DMEM) containing 1%
bovine calf serum was used.
Animal experiments. All experiments using live mice were performed in strict
accordance with the Guidelines and Regulations for the Care and Use of Laboratory
Animals in AAALAC-accredited facilities, and were approved by the Animal Policy
and Welfare Committee of the Yonsei University College of Medicine (Permit
number: 10-026).
Transgenic mice. The 2PLEASE constructs were digested with SfiI and ScaI, and a
DNA fragment of 12.6 kb was purified and thenmicroinjected into fertilized one-cell
pronuclei (C57BL/6N x C57BL/6N), using standard techniques. The genotypes of
mice were determined by genomic PCR using primers 59-CTCCTGACTACTC-
CCAGTCATAGC-39 and 59- GGCGGGCCATTTACCGTAAGTTAT-39. The R26-
Cre-ERT2 mouse was a generous gift from Dr. T. Jacks28.
Adenoviral administration and bioluminescence imaging. Adenoviruses encoding
Cre (Ad5CMVCre) and EGFP (Ad5CMVEGFP) were purchased from the Gene
Transfer Vector Core at the University of Iowa47. Each mouse was injected with 1.63
108 pfu of adenovirus through the lateral tail vein. Bioluminescence imaging was
performed as described previously34. Briefly, the abdominal area of skin was depilated
using depilatory cream 1 day before imaging. On the day of imaging, mice were
intraperitoneally injected with D-luciferin (150 mg/kg) and bioluminescence
imaging was performed using the IVIS Imaging System (Caliper Life Sciences,
Alameda, CA, USA).
Histopathological analysis and fluorescence imaging of tumor tissues. After
euthanizing mice, their livers were removed and rinsed in phosphate-buffered saline
(PBS). Samples collected from the livers were fixed overnight in freshly prepared
neutral-buffered formalin. Fixed tissue samples were embedded in paraffin. Sections
(5 mm) were placed on slides and stained with hematoxylin and eosin (H&E) and
PAS. Liver lesions were assessed by certified pathologists in accordance with the
criteria established by Frith et al31.
For fluorescence imaging of tumor cells in the liver, tumor-bearing mice were
perfused with 10 mL of saline followed by 10 mL of 4% paraformaldehyde after
anesthesia. After cutting with scissors, one part of the tumor was transferred to
Figure 6 | Robust transgene expression in the skin following Cre-mediated DNA excision. (A) Bioluminescence imaging of the dorsal skin of 2PLEASE;
R26-Cre-ERT2 double-transgenic mice at 1 week post-treatment with vehicle (left panel) and tamoxifen (right panel). (B) Basal cells in the dorsal
skin of these mice were imaged via in vivo green fluorescence imaging. Numerous skin cells in the basal layer expressed EGFP following tamoxifen
treatment, while no detectable signals were found in the layer of vehicle-treated mice (Tile-scanned images, scale bars, 200 mm). (C) Average
bioluminescent signals from the dorsal skin ofmice at the indicated time points after topical treatment with tamoxifen or vehicle. Note that no increases in
bioluminescence signals were observed from the tamoxifen-treated mice over several months.
www.nature.com/scientificreports
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neutral-buffered formalin and fixed overnight followed by paraffin embedding (for
H&E and PAS), and the remaining part of tumor tissue was stored in 4% para-
formaldehyde at 4uC with gentle agitation for 11 hrs. The fixed tissue was stored in
PBS with 1 mMMgCl2 at 4uC overnight and then sectioned into 100-mm-thick slices
using a vibratome (VT1000S, Leica). Mounting and fluorescence imaging were per-
formed as described previously48. Images were acquired using a confocal laser scan-
ning microscope (LSM710, Zen 2009 software, Carl Zeiss) mounted on an inverted
microscope (Axio Observer.Z1, Carl Zeiss). EGFP was excited with a 488-nm laser
line and a band-pass filter (505–530 nm wavelength) was used to detect emission
from EGFP.
Quantitative RT-PCR. RNA was isolated from mouse liver tissue using TRIzol
(Invitrogen, Carlsbad, USA), according to themanufacturer’s instructions. Following
treatment with 1 U/mL DNase I (Invitrogen, Carlsbad, CA, USA), 1 mg of RNA was
used for reverse-transcription (Superscript III RT, Invitrogen, Carlsbad, USA),
according to the manufacturer’s instructions. Real-time PCR was carried out on an
Applied Biosystems 7500 thermocycler using the following conditions: 95uC for
10 min, followed by 40 cycles at 95uC for 15 s and 60uC for 1 min, followed by a hold
at 4uC. The sequences of the primers used for qRT-PCR are listed in Supplementary
Table S1 online.
Hydrodynamic injection. The plasmids pT2/EGFP, pT2/shp53, and pPGK-SB13
were described previously34. Transposon plasmids pT2/KRASG12D and pT2/P53R172H
were generated by replacing the EGFP cDNA in pT2/EGFP with cDNA encoding
KRASG12D and pT2/P53R172H, respectively.
Hydrodynamic injection was performed as described previously34.
Topical application of tamoxifen and in vivo fluorescence imaging of the skin.The
hair in a 2.5 3 2.5-cm area of the lower part of the dorsal skin of the 2PLEASE mice
was clipped using electric clippers (Oster, USA). A depilatory agent was applied to the
clipped area for 1 min. A 100-mL aliquot of tamoxifen in ethanol (50 mg/mL) was
topically applied to the depilated area for three consecutive days. For low-dose
treatment, a 100-mL aliquot of tamoxifen in ethanol (10 mg/mL)was topically applied
to the depilated area once. Detailed procedures for in vivo fluorescence imaging of
EGFP-expressing cells in the skin are described elsewhere37,38. Basal cells in a large
area of skin were imaged by the ‘‘Tile scan’’ function using the motorized scanning
stage of a confocal laser scanning microscope (LSM 710, Zen 2009 software, Carl
Zeiss) with a 20X lens (NA 0.8, Plan-Apochromat).
Statistical analysis. The quantitative RT-PCR data and bioluminescence signals were
expressed as the mean 6 SD with sample sizes n 5 3 or larger. Statistical analyses of
these data were conducted via an unpaired parametric Student’s t test. Kaplan–Meier
survival data were evaluated using a log-rank test. A p value of less than 0.05 was
considered statistically significant.
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